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Oncogenic Activation of MEK/ERK Primes Melanoma
Cells for Adaptation to Endoplasmic Reticulum Stress
Amanda Croft1,2,6, Kwang H. Tay1,6, Suzanah C. Boyd3, Su T. Guo4, Chen C. Jiang1, Fritz Lai1, Hsin-Yi Tseng1,
Lei Jin1, Helen Rizos3, Peter Hersey5 and Xu D. Zhang1
Cancer cells commonly undergo chronic endoplasmic reticulum (ER) stress, to which the cells have to adapt for
survival and proliferation. We report here that in melanoma cells intrinsic activation of the ER stress response/
unfolded protein response (UPR) is, at least in part, caused by increased outputs of protein synthesis driven by
oncogenic activation of mitogen-activated protein kinase kinase/extracellular signal–regulated kinase (MEK/ERK)
and promotes proliferation and protects against apoptosis induced by acute ER stress. Inhibition of oncogenic
BRAFV600E or MEK-attenuated activation of inositol-requiring enzyme 1 (IRE1) and activating transcription factor 6
(ATF6) signaling of the UPR in melanoma cells. This was associated with decreased phosphorylation of eukaryotic
initiation factor 4E (eIF4E) and nascent protein synthesis and was recapitulated by knockdown of eIF4E. In line
with this, introduction of BRAFV600E into melanocytes led to increases in eIF4E phosphorylation and protein
production and triggered activation of the UPR. Similar to knockdown of glucose-regulated protein 78 (GRP78),
inhibition of XBP1 decelerated melanoma cell proliferation and enhanced apoptosis induced by the pharmaco-
logical ER stress inducers tunicamycin and thapasigargin. Collectively, these results reveal that potentiation of
adaptation to chronic ER stress is another mechanism by which oncogenic activation of the MEK/ERK pathway
promotes the pathogenesis of melanoma.
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INTRODUCTION
The endoplasmic reticulum (ER) responds to ER stress that is
characterized by accumulation and aggregation of unfolded
and/or misfolded proteins in the ER lumen by activation of a
range of signaling pathways to alter transcriptional and
translational programs (Harding et al., 2002; Schroder and
Kaufman, 2005; Walter and Ron, 2011; Wang and Kaufman,
2012). This couples the ER protein folding load with the ER
protein folding capacity and is termed the ER stress response
or the unfolded protein response (UPR) (Harding et al.,
2002; Schroder and Kaufman, 2005; Walter and Ron, 2011;
Wang and Kaufman, 2012). The UPR of mammalian cells is
initiated by three ER transmembrane proteins, activating
transcription factor 6 (ATF6), inositol-requiring enzyme 1
(IRE1), and double-stranded RNA-activated protein kinase-
like ER kinase (PERK) (Harding et al., 2002; Schroder and
Kaufman, 2005; Walter and Ron, 2011; Wang and Kaufman,
2012), which are anchored by the ER chaperon glucose-
regulated protein 78 (GRP78) at their luminal domains, but
upon ER stress, sequestration of GRP78 by unfolded proteins
causes their activation through inducing phosphorylation
and homodimerization of IRE1 and PERK and relocation of
ATF6 to the Golgi where it is cleaved and activated
as a transcriptional factor (Harding et al., 2002; Schroder
and Kaufman, 2005; Walter and Ron, 2011; Wang and
Kaufman, 2012).
The UPR is fundamentally a cyto-protective response,
but excessive or prolonged UPR can trigger cell death
predominantly by induction of apoptosis (Xu et al., 2005;
Boyce and Yuan, 2006). This is associated with attenuation
of IRE1 and ATF6 activities, whereas PERK signaling that is
essential for activation of pro-apoptotic proteins such as
CHOP and Bim is maintained (Puthalakath et al., 2007;
Tabas and Ron, 2011; Zhang et al., 2011). The UPR is often
constitutively activated in cancer cells, indicative of
adaptation to ER stress (Ma and Hendershot, 2004; Lee,
2007; Jiang et al., 2009b, 2009c; Wang et al., 2010).
Indeed, cells in a developing solid cancer may undergo
hypoxia, nutrient starvation, and acidosis, thus resulting in
ER stress (Ma and Hendershot, 2004; Lee, 2007; Wang et al.,
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2010). Moreover, increased synthesis of proteins that are often
in mutated forms required to sustain malignancy of cancer
cells may also directly uncouple the ER protein folding load
with the ER protein folding capacity (Ma and Hendershot,
2004; Lee, 2007).
The rate of protein synthesis is primarily controlled at the
stage of mRNA translation initiation (Bilanges and Stokoe,
2007; Silvera et al., 2010; Bitterman and Polunovsky, 2012;
Grzmil and Hemmings, 2012). Initiation of translation of most
mRNAs is mediated by the cap-dependent mechanism, which
is governed by the eukaryotic initiation factor 4F (eIF4F)
complex that consists of the cap-binding protein eIF4E, the
RNA helicase eIF4A, and the scaffolding protein eIF4G
(Bilanges and Stokoe, 2007; Silvera et al., 2010; Bitterman
and Polunovsky, 2012; Grzmil and Hemmings, 2012). Among
them, eIF4E is the rate-limiting factor (Sonenberg and
Hinnebusch, 2009; Jackson et al., 2010; Silvera et al.,
2010). Although the activity of eIF4E is negatively regulated
by eIF4E binding proteins (4E-BPs), it is enhanced with
phosphorylation at serine 209 by MAP kinase signal-
integrating kinase 1 (MNK1) and MNK2 upon binding to
eIF4G (Phillips and Blaydes, 2008; Sonenberg and
Hinnebusch, 2009; Jackson et al., 2010; Silvera et al., 2010;
Hou et al., 2012).
A characteristic of human melanoma is constitutive activa-
tion of the MEK/ERK (mitogen-activated protein kinase kinase/
extracellular signal–regulated kinase) pathway (Davies et al.,
2002; Platz et al., 2008). This stems primarily from oncogenic
mutations of BRAF, with the most common mutation being
a glutamic acid for valine substitution at position 600
(BRAFV600E) (Davies et al., 2002; Platz et al., 2008).
Mutations in N-RAS, H-RAS, c-Kit, ERBB4, or the G-protein
a-subunit GNAQ are also responsible in subsets of melanomas
(Flaherty et al., 2010). Activation of MEK/ERK is critical for
melanoma cell survival under acute, pharmacological ER
stress (Jiang et al., 2007; Hersey and Zhang, 2008), but its
potential role in adaptation of melanoma cells to chronic,
constitutive ER stress remains to be determined. It is known
that MEK/ERK signaling promotes protein synthesis (Bilanges
and Stokoe, 2007; Silvera et al., 2010; Bitterman and
Polunovsky, 2012; Grzmil and Hemmings, 2012), which
may contribute to increased ER protein folding load in cells
with MEK/ERK constitutively activated. However, it was
recently reported that the RAF inhibitor vemurafenib
induced ER stress, implicating that activation of MEK/ERK
may alleviate ER stress in BRAFV600E melanoma cells (Beck
et al., 2013).
In this study, we have examined the potential interaction
between the constitutively activated MEK/ERK pathway and
the UPR in melanoma cells. We show here that MEK/ERK
signaling is necessary and sufficient for intrinsic activation of
the UPR as a consequence of ER stress triggered by enhanced
protein synthesis, which in turn promotes proliferation and
protects against apoptosis induced by acute ER stress in
melanoma cells. These results indicate that potentiation of
adaptation to chronic ER stress is another mechanism by
which activation of the MEK/ERK pathway promotes the
pathogenesis of melanoma.
RESULTS AND DISCUSSION
The mutant BRAF inhibitor PLX4720 attenuates activation of the
IRE1 and ATF6 branches of the UPR in BRAFV600E melanoma
cells
Past studies have shown that activation of MEK/ERK is required
for induction of high levels of UPR and contributes to resistance
of melanoma cells to acute, pharmacological ER stress (Jiang
et al., 2007; Hersey and Zhang, 2008). To study whether
activation of MEK/ERK similarly contributes to chronic,
constitutive activation of the UPR in melanoma cells, we
tested the effect of the mutant BRAF inhibitor PLX4720 on
the expression of the active (spliced) form of XBP1 (XBP1s)
mRNA and GRP78, two commonly used indicators of activation
of the IRE1 and ATF6 branches of the UPR (Ma and Hendershot,
2004; Lee, 2007), in melanoma cell lines. Strikingly, while
XBP1s and GRP78 were downregulated in Mel-RMu and
MM200 cells harboring BRAFV600E, they were both increased
in Mel-RM cells carrying wild-type BRAF, by PLX4720
(Figure 1a–d). Moreover, PLX4720 triggered decreases in phos-
phorylated (activated) IRE1a and cleaved (activated) ATF6 in
Mel-RMu and MM200 cells (Figure 1e and f) but caused, albeit
moderately, increases in activated IRE1a and ATF6 in Mel-RM
cells (Supplementary Figure S1a online). These contrasting
effects of PLX4720 were associated with its different impacts
on activation of ERK, which was, as anticipated, inhibited in
BRAFV600E, but enhanced in wild-type BRAF, melanoma cells
(Supplementary Figure S1b online) (Hatzivassiliou et al., 2010).
PLX4720 neither reduced the levels of phosphorylated eIF2a
and ATF4, downstream targets of PERK signaling, in Mel-RMu
and MM200 cells, nor did it increase their expression in Mel-
RM cells, suggesting that it preferentially impinges on activation
of IRE1 and ATF6 signaling (Supplementary Figure S2 online).
The inhibitory effect of PLX4720 on activation of IRE1 and ATF6
signaling was confirmed in another 4 BRAFV600E cell lines as
shown by downregulation of XBP1s and GRP78 (Supplementary
Figure S3 online).
In contrast to inhibition of IRE1a and ATF6 signaling by
PLX4720, the mutant BRAF inhibitor vemurafenib, a close
relative of PLX4720 (Tsai et al., 2008), has recently been
reported to induce ER stress in BRAFV600E melanoma cells
(Beck et al., 2013). To clarify this paradox, we treated Mel-
RMu, MM200, and Mel-RM cells with vemurafenib. Indeed,
vemurafenib upregulated XBP1s and GRP78 in Mel-RMu and
MM200 cells, but strikingly, also caused upregulation of
XBP1s and GRP78 in Mel-RM cells (Supplementary Figure
S4a–d online). Nonetheless, vemurafenib inhibited ERK acti-
vation in Mel-RMu and MM200 cells and enhanced activation
of ERK in Mel-RM cells, recapitulating the different effects of
PLX4720 on ERK activation in BRAFV600E and wild-type BRAF
melanoma cells (Supplementary Figure S4e and S4f online).
These results suggest that induction of ER stress by vemur-
afenib may be disassociated with its effects on activation of
MEK/ERK signaling.
Inhibition of MEK or knockdown of ERK1/2 blocks IRE1 and
ATF6 signaling in BRAFV600E and wild-type BRAF melanoma cells
To confirm that the contrasting effects of PLX4720 on activa-
tion of IRE1 and ATF6 signaling are due to its different effects
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on activation of MEK/ERK in BRAFV600E and wild-type BRAF
melanoma cells, we treated Mel-RMu and MM200
(BRAFV600E) and Mel-RM (wild-type BRAF) cells with the
MEK inhibitor U0126. Inhibition of MEK downregulated
XBP1s and GRP78 not only in BRAFV600E but also in wild-
type BRAF melanoma cells (Figure 2a and b and Supple-
mentary Figure S5 online). In line with this, concurrent
knockdown of ERK1/2 with small interfering RNA (siRNA)
reduced the levels of XBP1s and GRP78 in both the Mel-RMu
and Mel-RM cells (Figure 2c–e).
We also examined the effect of the other mutant BRAF
inhibitor dabrafenib on XBP1 and GRP78 in melanoma cells.
Dabrafenib downregulated XBP1s and GRP78 and inhibited
ERK activation in MM200 but upregulated XBP1s and GRP78
and enhanced ERK activation in Mel-RM cells, recapitulating
the contrasting effects of PLX4720 on activation of IRE1 and
ATF6 signaling in BRAFV600E and wild-type BRAF melanoma
cells (Supplementary Figures S6a–c and S7a–c online). In
contrast, the BRAF inhibitor CEP32496 that inhibits both
BRAFV600E and wild-type BRAF reduced XBP1s and GRP78
and inhibited ERK activation in both the MM200 and Mel-RM
cells (Supplementary Figures S6a–c and S7a–c online) (James
et al., 2012). Taken together, the above results suggest that
constitutive activation of MEK/ERK signaling triggers ER stress
in melanoma cells and that induction of ER stress by PLX4720
and dabrafenib in wild-type BRAF melanoma cells is
associated with enhanced activation of ERK rather than
caused by off-target effects of the inhibitors.
Activation of MEK/ERK signaling is critical for sustaining de novo
protein production in melanoma cells
Activation of the MEK/ERK pathway promotes protein synth-
esis that is often enhanced in cancer cells and may represent
an underlying mechanism of chronic ER stress by uncoupling
the ER protein folding load with the ER protein folding
capacity (De Benedetti and Graff, 2004; Silvera et al., 2010).
Indeed, the magnitude of nascent protein production was
significantly higher in melanoma cells than melanocytes
(Figure 3a), which was, however, reduced by U0126 in both
the BRAFV600E (Mel-RMu and MM200) and wild-type BRAF
(Mel-RM) melanoma cells (Figure 3b). Similarly, PLX4720
reduced protein synthesis in Mel-RMu and MM200 cells but
increased the synthesis in Mel-RM cells (Figure 3c). Thus,
constitutive activation of MEK/ERK has an important role in
maintaining high levels of protein production in melanoma
cells. Notably, neither U0126 nor PLX4720 inhibits protein
synthesis in melanocytes (Figure 3b and c).
MEK/ERK-mediated activation of protein synthesis involves
phosphorylation of the translation initiator eIF4E (Phillips and
Blaydes, 2008; Hou et al., 2012). Consistent with this, the
basal levels of phosphorylated eIF4E were generally higher in
melanoma cells than melanocytes (Supplementary Figure S8
online), which were rapidly reduced by PLX4720 in
BRAFV600E, and by U0126 in both the BRAFV600E and wild-
type BRAF, melanoma cells (Figure 3d–g), suggesting that the
increased protein production in melanoma cells is coupled
with phosphorylation of eIF4E mediated by MEK/ERK.
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Figure 1. PLX4720 inhibits activation of the IRE1 and ATF6 pathways of the unfolded protein response in BRAFV600E melanoma cells. (a) Reverse transcription–
PCR analysis showing that PLX4720 (3mM) alters the expression of XBP1s mRNA (n¼3). (b, c) qPCR analysis showing that PLX4720 (3mM) alters the expression of
XBP1s (b) and glucose-regulated protein 78 (GRP78) (c) mRNA (n¼ 3, mean±SEM; Student’s t-test; *Po0.05). (d–f) Whole-cell lysates from cells with or without
PLX4720 (3mM) treatment for the indicated periods were subjected to western blot analysis (n¼3). ATF6, activating transcription factor 6; DMSO, dimethyl
sulfoxide; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IRE1, inositol-requiring enzyme 1.
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MEK/ERK signaling triggers chronic ER stress through increased
protein production in melanoma cells
To examine whether increased protein synthesis mediated by
the MEK/ERK pathway causes ER stress, we treated MM200
and Mel-RM cells with the small molecule 4EGI-1, an
inhibitor of eIF4E (Moerke et al., 2007; Fan et al., 2010).
4EGI-1 at a concentration (10mM) that did not induce notice-
able cell death caused partial, but significant, inhibition of
protein synthesis (Figure 4a). This was associated with down-
regulation of XBP1s and GRP78 (Figure 4b and c), recapitulat-
ing, at least in part, the effects of inhibition of MEK/ERK on
protein synthesis and activation of the UPR (Figures 1–3). In
addition, 4EGI-1 abolished enhancement in protein synthesis
and upregulation of XBP1s and GRP78 triggered by PLX4720
in Mel-RM cells (Supplementary Figure S9a–c online). These
results suggest that MEK/ERK-induced activation of the UPR is
mediated by eIF4E.
We confirmed the role of enhanced protein synthesis in
MEK/ERK-induced ER stress by knocking down eIF4E with
siRNA (Figure 4d), which significantly inhibited de novo
protein synthesis and reduced XBP1s and GRP78 transcript
expression in MM200 and Mel-RM cells (Figure 4e and f, and
Supplementary Figure S10a online), in line with the role of
eIF4E and increased protein synthesis in induction of ER stress.
In support of this, introduction of a construct expressing the
phosphomimetic S209D (serine-to-aspartic acid) eIF4E mutant
into Mel-RM cells caused an increase in nascent protein
synthesis and GRP78 and XBP1s expression and abolished
reduction in protein synthesis and inhibition of XBP1s and
GRP78 induced by U0126 (Figure 4g–i and Supplementary
Figure S10b online).
Oncogenic BRAF activates eIF4E and the UPR in melanocytes
To further confirm that activation of MEK/ERK signaling
induces ER stress in melanocytic cells, we infected HEM-
1455 human melanocytes with a lentiviral construct expres-
sing BRAFV600E. Enforced expression of BRAFV600E caused
activation of ERK, which was associated with induction of
phosphorylation of eIF4E (Figure 5a and b), increased protein
synthesis, albeit moderately, and activation of IRE1 and ATF6
signaling of the UPR (Figure 5c–e). In contrast, overexpression
of wild-type BRAF did not increase ERK activation, consistent
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with previous reports (Scurr et al., 2010), nor did it cause
activation of IRE1 and ATF6 signaling (Supplementary Figure
S11 online). Intriguingly, the expression levels of phosphory-
lated eIF2a and ATF4 were also increased moderately by
ectopic expression of BRAFV600E in melanocytes (Figure 5a).
Regardless, these data not only confirm the role of activation
of MEK/ERK in causing chronic ER stress but also suggest that
occurrence of ER stress is an early event in the pathogenesis of
melanoma. Indeed, BRAFV600E is found in the majority of nevi
(Pollock et al., 2003; Michaloglou et al., 2005; Taube et al.,
2009), and the UPR is activated at early stages of melanoma
initiation by HRASG12V (Denoyelle et al., 2006). Interestingly,
oncogenic BRAF induces senescence in melanocytes
(Dhomen et al., 2009; Scurr et al., 2010), but once the
senescence barrier is overcome, it drives melanomagenesis
(Dhomen et al., 2009; Scurr et al., 2010). By analogy,
induction of ER stress by oncogenic activation of MEK/ERK
signaling in melanocytic cells may also set a barrier for
melanoma initiation. It is conceivable that only those cells
that can survive chronic ER stress triggered by MEK/ERK may
acquire malignant phenotypes.
XBP1 and GRP78 promote proliferation of melanoma cells
We examined the functional consequence of constitutive
activation of IRE1 and ATF6 signaling in melanoma cells.
Although siRNA knockdown of XBP1 or GRP78 did not
trigger noticeable cell death, it inhibited proliferation in
MM200 and Mel-RM cells (Figure 6a and b, and
Supplementary Figure S12 online), However, knockdown
of XBP1 or GRP78 did not impact on inhibition of
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proliferation caused by PLX4720 in MM200 cells or by
U0126 in MM200 and Mel-RM cells (Figure 6c and d), in
line with downregulation of XBP1 and GRP78 by inhibition
of MEK/ERK signaling (Figures 1a–d and 2a–c). These results
suggest that XBP1 and GRP78 activated by MEK/ERK signal-
ing primarily affect proliferation of melanoma cells under
steady-state conditions. Notably, both PLX4720 and U0126
primarily exert inhibitory effects on cell proliferation at the
concentrations (3 and 20 mM, respectively) used in this study,
although they can induce cell death when used at higher
concentrations in a proportion of melanoma cell lines (Wang
et al., 2007; Jiang et al., 2011). The effect of XBP1 on
melanoma cell proliferation was also shown by treatment of
MM200 and Mel-RM cells with salicylaldehyde that inhibits
the IRE1 endonuclease activity, thus blocking generation of
XBP1s (Figure 6e) (Volkmann et al., 2011). Intriguingly,
overexpression of XBP1 or GRP78 did not protect sensitive
melanoma cells from PLX4720- or U0126-induced
inhibition of proliferation (Supplementary Figures S13 and
S14 online), suggesting that XBP1 or GRP78 at levels above
those driven by MEK/ERK signaling does not provide further
proliferative advantage to melanoma cells under steady-state
conditions.
Activation of IRE1/XBP1 signaling contributes to survival of
melanoma cells undergoing acute ER stress
Induction of ER stress that potentially leads to cell death by
MEK/ERK signaling seems paradoxical, as its activation has
been well established to be protective against cellular stress in
melanoma cells (Hersey et al., 2006; Jiang et al., 2007).
Nevertheless, MEK/ERK-mediated induction of GRP78 has an
important role in protecting melanoma cells from apoptosis
induced by pharmacological ER stress (Jiang et al., 2007).
Similarly, IRE1/XBP1 signaling also contributed to survival of
melanoma cells undergoing pharmacological ER stress, in that
treatment with salicylaldehyde or siRNA knockdown of XBP1
enhanced apoptosis of MM200 and Mel-RM cells in response
to the ER stress inducers tunicamycin or thapsigargin
(Supplementary Figures S15a–c online). Therefore, chronic
activation of IRE1 and ATF6 signaling not only promotes
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melanoma cell proliferation but also protects melanoma cells
from apoptosis undergoing acute ER stress, which conceivably
has a role in resistance of melanoma cells to therapeutic
agents that induce ER stress (Jiang et al., 2009a).
As downregulation of protein phosphatase 2 (PP2A) activity
is an important protective mechanism against pharmacologi-
cal ER stress in melanoma cells (Tay et al., 2012), we
examined whether constitutive activation of MEK/ERK
signaling that causes chronic ER stress has a role in
regulation of PP2A activity. PLX4720 did not impinge on the
phosphatase activity of PP2A in MM200 cells (Supplementary
Figure S16a online), indicating that relief of melanoma cells
from MEK/ERK-triggered chronic ER stress is unable to
enhance PP2A activity conceivably due to attenuation of
feedback regulation of PP2A by ERK (Garcia et al., 2002;
Letourneux et al., 2006). Nevertheless, it reduced PP2A
activity in Mel-RM cells (Supplementary Figure S16b online),
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consistent with downregulation of PP2A activity by induction
of ER stress (Tay et al., 2012). It seems likely that while acute
ER stress downregulates PP2A activity, constitutive activation
of MEK/ERK has a role in keeping PP2A activity in check to a
minimal level. PP2A is known to have a tumor-suppressive
role in many types of cancer (Janssens et al., 2005; Kalev and
Sablina, 2011).
Introduction of exogenous oncogenic BRAF has been
reported to inhibit melanoma cell growth by inducing autop-
hagy (Maddodi et al., 2010). However, the mechanism(s)
involved remains unknown. Our results suggest that this may
be associated with induction of ER stress by activation of MEK/
ERK signaling, in that ER stress is known to trigger autophagy,
which is nevertheless believed to have a protective role in
cells undergoing ER stress (Li et al., 2008). As melanoma cells
carrying endogenous oncogenic BRAF are additive to its
signaling for survival and growth (Hoeflich et al., 2006), it is
unlikely that autophagy, if any, resulting from constitutive
chronic ER stress that is pro-proliferative inhibits BRAFV600E
melanoma cell growth.
Although we have clearly demonstrated that constitutive
activation of MEK/ERK signaling is not only a mechanism of
adaptation to ER stress but also a source of chronic ER stress in
melanoma cells, it remains puzzling how MEK/ERK signaling
spares the PERK branch, the main pathway that mediates ER
stress–induced apoptosis (Xu et al., 2005; Boyce and Yuan,
2006; Puthalakath et al., 2007). It is believed that there is no
ER stress inducer that can selectively elicit any particular
signaling pathway of the UPR (Lin et al., 2007; Walter and
Ron, 2011). Indeed, activation of MEK/ERK signaling by
ectopic expression of BRAFV600E resulted in activation of all
the three branches of the UPR in melanocytes. As IRE1 and
ATF6 activities are progressively attenuated, whereas PERK
signaling is maintained and thus triggers apoptosis in many
types of cells undergoing prolonged ER stress (Lin et al., 2007),
it is possible that activation of MEK/ERK exerts a role in
sustaining IRE1 and ATF6 activities, rather than selectively
activating the pathways in melanoma cells. Also, while
induction of ER stress by MEK/ERK signaling is resolved,
other elements such as increased glycolysis and cellular
acidosis are still able to trigger ER stress in melanoma cells
(Ma and Hendershot, 2004; Liu et al., 2009; Zhuang et al.,
2010). Under such conditions, IRE1 and ATF6 activities are
attenuated with diminishing of MEK/ERK signaling, whereas
persistent ER stress continues driving activation of the PERK
pathway.
Another paradox that needs to be clarified is how vemur-
afenib induces ER stress in both the BRAFV600E and wild-type
melanoma cells, although our results indicate that the ability of
vemurafenib to induce ER stress in melanoma cells may be
independent of its effect on activation of MEK/ERK signaling.
This is of particular importance, as it suggests that the
therapeutic efficacy of this clinically available BRAF inhibitor
may be determined not only by its inhibitory effect on MEK/
ERK but also by its ability to induce ER stress. Further studies
using animal models and melanoma samples from patients
before and after treatment with the inhibitor are clearly
warranted.
MATERIALS AND METHODS
Cell lines
Human melanoma cell lines Mel-RMu, MM200, Mel-CV, IgR3,
A2058, and SkMel-28 (BRAFV600E); and Mel-RM, Mel-JD, ME4405,
and ME1007 (BRAFWT); and human melanocyte lines HEMn-MP and
HEMn-DP were obtained and cultured as described previously (Jiang
et al., 2010; Ye et al., 2013).
Antibodies and other reagents
Antibodies and reagents used are listed in Supplementary Table S1
and S2 online.
Apoptosis
Quantitation of apoptotic cells was carried out by measurement of
sub-G1 DNA content as described elsewhere (Jiang et al., 2011).
Western blot analysis
Western blot analysis was carried out as described previously (Jiang
et al., 2011). Labeled bands were detected by Luminata Crescendo
Western HRP substrate (Millipore, Billerica, MA). Images were
captured, and the intensity of the bands was quantitated with
ImageReader LAS-4000 (Fujifilm, Tokyo, Japan).
Detection of spliced XBP1 mRNA (XBP1s)
Detection of XBP1s was carried out as previously described (Jiang
et al., 2008).
Lentiviral gene transduction and DNA constructs
The lentiviral vector pCDH-CMV-MCS-EF1-copGFP containing Myc-
tagged BRAFV600E or BRAFWT was used to produce lentiviruses and to
transduce human melanocytes as described previously (Haferkamp
et al., 2009). Overexpression of BRAFV600E and BRAFWT was
confirmed by western blot using Myc tag and BRAF antibody,
respectively.
siRNA knockdown
Transfection of siRNA siGENOME SMARTpools (Supplementary
Table S4 online) was carried out as described previously (Jiang
et al., 2011).
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